OPKO Health, the Miami healthcare company, announced Friday it has purchased Prost-Data, which operates the Nashville-based OURLab, a company with 18 blood-testing sites through the United States and a sales force that deals mainly with urologists..
OPKO said the deal provides it with a commercial platform to launch sales of its 4Kscore, which offers a new approach to testing for prostate cancer.
In a press release, the company said 4Kscore “may reduce the number of unnecessary prostate biopsies by 50 percent or more.”
In a filing with the Security and Exchange Commission, OPKO said that Prost-Data has one shareholder, Jonathan Oppenheimer, a physician. OPKO will pay Oppenheimer’s company $9.4 million plus $30.6 million in OPKO shares.